---
figid: PMC4020326__jdi-5-251-g1
figtitle: Diverse mechanistic pathways of metformin
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- unidentified
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC4020326
filename: jdi-5-251-g1.jpg
figlink: /pmc/articles/PMC4020326/figure/jdi12208-fig-0001/
number: F1
caption: Diverse mechanistic pathways of metformin. Metformin reduces adenosine triphosphate
  (ATP) production, increasing the cellular adenosine monophosphate (AMP)‐to‐ATP ratio,
  which leads to the activation of the liver kinase B1 (LKB1)–AMP activated protein
  kinase (AMPK) signaling pathway. Subsequently, LKB1 activates AMPK. AMPK inhibits
  mammalian target of rapamycin complex 1 (mTORC1) directly and the mTOR‐inhibitor
  through tuberous sclerosis complex (TSC)1/2 activation. Such mTORC1‐inhibition results
  in the inhibition of several carcinogenic molecules, such as ribosomal protein S6
  kinase (S6K) and hypoxia‐inducible factor‐1α (HIF‐1α). Several growth factors induce
  protein‐kinase B (PKB)/Akt activation and counteract with AMPK‐mediated TSC1/2 activation.
  Alternatively, metformin inhibits Rag‐guanosine triphosphatase (GTPase), which activates
  mTORC1.
papertitle: Cancer biology in diabetes.
reftext: Shi Sen, et al. J Diabetes Investig. 2014 May 4;5(3):251-264.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9446946
figid_alias: PMC4020326__F1
figtype: Figure
redirect_from: /figures/PMC4020326__F1
ndex: fd49c646-deec-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4020326__jdi-5-251-g1.html
  '@type': Dataset
  description: Diverse mechanistic pathways of metformin. Metformin reduces adenosine
    triphosphate (ATP) production, increasing the cellular adenosine monophosphate
    (AMP)‐to‐ATP ratio, which leads to the activation of the liver kinase B1 (LKB1)–AMP
    activated protein kinase (AMPK) signaling pathway. Subsequently, LKB1 activates
    AMPK. AMPK inhibits mammalian target of rapamycin complex 1 (mTORC1) directly
    and the mTOR‐inhibitor through tuberous sclerosis complex (TSC)1/2 activation.
    Such mTORC1‐inhibition results in the inhibition of several carcinogenic molecules,
    such as ribosomal protein S6 kinase (S6K) and hypoxia‐inducible factor‐1α (HIF‐1α).
    Several growth factors induce protein‐kinase B (PKB)/Akt activation and counteract
    with AMPK‐mediated TSC1/2 activation. Alternatively, metformin inhibits Rag‐guanosine
    triphosphatase (GTPase), which activates mTORC1.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ATP8A2
  - APRT
  - MFAP1
  - AKT1
  - PTK2B
  - STK11
  - SLC12A3
  - TSC1
  - TESC
  - TSC2
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - MTOR
  - Akt1
  - Akt2
  - Stk11
  - Slc12a3
  - Tsc22d1
  - Mtor
  - ATPsynbeta
  - Atpalpha
  - Amph
  - Akt
  - Lkb1
  - Tsc
  - Tsc1
  - SNF4Agamma
  - AMPKalpha
  - Tor
---
